Quality of survival of patients with brain gliomas treated with postoperative CCNU and radiation therapy

Abstract

This prospective randomized clinical trial compared the effectiveness of combined treatment with CCNU and radiation therapy to the use of radiation therapy alone for the postoperative management of supratentorial brain gliomas (67% anaplastic) in 198 patients. The results were evaluated with the aid of a specially developed weighted neuropsychological test battery providing single-value estimation of "life quality" of patients, as well as with a clinical performance scale. Based on these methods, it was established that patients improved within 6 months following therapy. This improvement was maintained in surviving patients during the 2-year follow-up period. The patients led a relatively normal life, but when their condition deteriorated their decline was rapid. The median survival time of patients treated with radiotherapy did not differ significantly from that of patients receiving chemotherapy in addition. Nor did the analysis of life quality and of changes in clinical performance show any benefit in supplementing surgery and radiation therapy with CCNU chemotherapy at the dosage used.

Quality of life in patients with intracranial tumors on the basis of Karnofsky's performance status

“…In patients with malignant astrocytomas, currently used therapeutic modalities include surgical resection, radiation therapy and chemotherapy alone or in combination [2,5,10,15,20,22]. The quality-of-life index remained at a higher level only for the first ten months after surgery.…”

Radiation Therapy of CNS-Tumors in Kiel University Hospital 1970–1979

“…The end-point of most clinical trials, including this retrospective analysis of the University of Kiel data, has been survival time, or time to tumor progression. With the limited gain in survival that has been demonstrated for postoperative radiotherapy, and for the various chemo therapeutic agents, it is important to examine the quality of survival during the short remaining lifetime of most of these patients [43,46]. There is a need for objective quality of life data that should be integrated into the design of future clini cal trials.…”

Health-related quality of life and symptom research in glioblastoma multiforme patients

“…In the study comparing postoperative radiation therapy for supratentorial glioma patients with combined treatment of radiation and CCNU chemotherapy, a weighted neuropsychologic test battery was applied as a HRQOL measure [80]. A sum score of all cognitive test results was calculated using a panel of expert neuropsychologists.…”